AQR Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

AQR Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,921	Closed	-$1.12M	–	2385
2022 Q2	$1.12M	Buy	+14,921	New	+$663K	﹤0.01%	1375
2022 Q1	–	Sell	-4,956	Closed	-$236K	–	2334
2021 Q4	$236K	Sell	4,956 -2,823	-36%	-$126K	﹤0.01%	2045
2021 Q3	$517K	Buy	+7,779	New	+$554K	﹤0.01%	1856
2021 Q2	–	Sell	-4,587	Closed	-$434K	–	2325
2021 Q1	$434K	Buy	4,587 +1,858	+68%	+$221K	﹤0.01%	1887
2020 Q4	$333K	Buy	+2,729	New	+$299K	﹤0.01%	1931
2020 Q3	–	Sell	-12,853	Closed	-$830K	–	2303
2020 Q2	$830K	Buy	+12,853	New	+$741K	﹤0.01%	1540

AQR Capital Management's TPTX Position: Q3 2022 in Review

AQR Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 14,921 shares — an estimated $1.12M sold.

AQR Capital Management first reported a position in TPTX in Q2 2020 and held it in 6 quarters. The position peaked at $1.12M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

AQR Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
AQR Capital Management sold 14,921 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.12M.
AQR Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
AQR Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.12M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.